Results 161 to 170 of about 94,246 (299)

From the Liver to Heart in Nonalcoholic Fatty Liver Disease: Single-Cell and Serum Evidence for Cytokeratin 18 in Predicting Cardiovascular Risk. [PDF]

Cardiovasc Ther
Xu H, Ma X, Chen F, Zhou B.
europepmc   +1 more source

Additional file 3 of Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation

, 2022
Yanan Chu, Fangcong Yu, Yakui Wu, Jinxiu Yang, Jiaran Shi, Tianxin Ye, Deheng Han, Xingxiang Wang   +7 more
openalex   +1 more source

Guidance for Liver Rehabilitation in Chronic Liver Disease

Hepatology Research, EarlyView.
ABSTRACT In April 2023, the Japan Society of Hepatology published its official guidelines on liver rehabilitation for chronic liver disease. In this article, we summarize the current evidence on the role of liver rehabilitation in slowing the progression of chronic liver disease, particularly metabolic dysfunction‐associated steatotic liver disease ...
Shuji Terai, Hiroteru Kamimura, Yoichi Hiasa, Norio Akuta, Toru Ishikawa, Yuichiro Eguchi, Hironao Okubo, Takumi Kawaguchi, Miwa Kawanaka, Tatsuo Kanda, Masaaki Korenaga, Ryotaro Sakamori, Masahito Shimizu, Yoshio Sumida, Ryosuke Tateishi, Atsushi Tanaka, Naoki Tanaka, Yasuo Tanaka, Yuki Tahata, Masato Nakai, Tadashi Namisaki, Takashi Nishimura, Atsushi Hiraoka, Takeshi Matsui, Nami Mori, Akio Moriya, Tetsuo Takehara   +26 more
wiley   +1 more source

Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease [PDF]

, 2019
Lan-Feng Xue, Wen-hui Luo, Li‐Hao Wu, Xing‐Xiang He, Harry Hua‐Xiang Xia, Yu Chen   +5 more
openalex   +1 more source

The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES) [PDF]

, 2020
Yun-Jung Yang, Mi‐Hyang Jung, Seok Hoo Jeong, Yeon‐Pyo Hong, Yeong In Kim, Sang Joon An   +5 more
openalex   +1 more source

Modern Diets, Metabolic Inequity, and Race–Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is quickly emerging as a global public health concern, primarily fueled by the rising consumption of processed and ultraprocessed foods. This global health issue, showing a 50% increase in prevalence over two decades to 38% of the global population, is now the second most common ...
Arunkumar Krishnan, Kunal C. Kadakia, Sean Richard Rudnick, Andrew S. deLemos, James Dewitt Miller, Ted Xiao, Mark W. Russo, Dionisios Vrochides, Andrew Schreiner, Ajay Dharod   +9 more
wiley   +1 more source

Oral Icariin Nanoparticles Ameliorate Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress. [PDF]

ACS Appl Mater Interfaces
Fan S, Ma N, Li J, Wang B, Zhao Y, Yao Y, Chai X, Zhou Z.   +7 more
europepmc   +1 more source

If treating obesity with GLP‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials

Diabetes, Obesity and Metabolism, EarlyView.
Anastasios Tentolouris, Ioannis Ntanasis‐Stathopoulos   +1 more
wiley   +1 more source

Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort

Journal of Internal Medicine, EarlyView.
Abstract Background and Aims Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, but its prevalence and severity remain poorly characterized in the general population. Our aim was to estimate the prevalence of MASLD and the risk of advanced fibrosis in a large Swedish general population ...
Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P. Andersson, Hannes Hagström   +10 more
wiley   +1 more source

Association of the Rs738409 Polymorphism in <i>PNPLA3</i> with Development and Severity of Nonalcoholic Fatty Liver Disease. [PDF]

Indian J Endocrinol Metab
Das M, Biswas A, Goswami S, Deb R, Das S, Ray D.   +5 more
europepmc   +1 more source